During the opening segment of this program on evidence-based decisions to improve quality and regulate costs, Peter Salgo, MD; John L. Fox, MD, MHA; Irwin W. Tischler, DO; Michael Kolodziej, MD; Ira M. Klein, MD, MBA, FACP; and Bryan Loy, MD, discuss how noninterventional studies play a role in oncology, and explore the variables that affect the clinical success of a treatment.
Providers take into account multiple factors when making decisions about appropriate therapy for their patients. Among the variables that they must consider are the high costs of care and personalized medicine.
Because personalized medicine is now taking on an increasingly important role in oncology, the information collected during noninterventional studies is extremely useful, according to Drs Tischler and Kolodziej.
Dr Fox explains that comparative data are not often distinguished during clinical trials. Noninterventional studies are important because the data collected during these studies can help determine whether or not a treatment is “optimal” for a patient. Dr Klein agrees and provides an example, noting that this information can help match specific patient populations to specific treatments based on their genetic mutations.
Despite their importance, Dr Tischler explains that the data collected during non-interventional studies will most likely never replace clinical trial data, because the information collected during clinical trials is considered the “gold standard” in healthcare.
However, Dr Loy remarks that the information collected during randomized clinical trials can suggest additional noninterventional studies in specific patient populations. He comments that providers need to be selective when determining an appropriate treatment option for patients.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Emily Goldberg Shares Insights as a Genetic Counselor for Breast Cancer Risk Screening
October 30th 2023On this episode of Managed Care Cast, Emily Goldberg, MS, CGC, a genetic counselor at JScreen, breaks down how genetic screening for breast cancer works and why it is so important to increase awareness and education around these screening tools available to patients who may be at risk for cancer.
Listen
Machine Learning Model Predicts Hepatocellular Carcinoma Risk in Patients With MASLD
March 22nd 2024Machine learning models have potential for early identification of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) who are at risk of hepatocellular carcinoma.
Read More